Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Rituximab in Japanese WM
NCT04062448Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in Waldenstrom macroglobulinemia (WM), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Response Rate. Started Sep 2019; status: completed.
02
Drugs
ibrutinib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04062448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062448.